Entry into the pharmaceutical manufacturing and marketing business and making 藤永製薬 a subsidiary

「Regarding business performance, at 第一三共エスファ株式会社, the 3 active ingredients and 7 products launched in December 2024 made a significant contribution, as did the prostate cancer treatment “Abiraterone Acetate Tablets (reference product: Zytiga® Tablets)” launched in December 2025 and the antiplatelet drugs “Prasugrel Tablets (reference product: Effient® Tablets)” and “Prasugrel OD Tablets (reference product: Effient® OD Tablets)” launched in March 2026. In addition, in February 2026, 第一三共エスファ株式会社 obtained marketing approvals for the allergy treatment drugs “Bilastine Tablets (reference product: Bilaxten® Tablets)” and “Bilastine OD Tablets (reference product: Bilaxten® Tablets),” and the selective SGLT2 inhibitor “Dapagliflozin Tablets (reference product: Forxiga® Tablets).”」

「Regarding business performance, 3 active ingredients and 7 products launched in December 2024 have made a significant contribution, and we aim to further expand market share. In December 2025, 第一三共エスファ株式会社 plans to launch the prostate cancer treatment “Abiraterone Acetate Tablets (reference product: Zytiga® Tablets).”」

「Sales of the generic drug “Zonisamide OD Tablets (reference product: Torelief® OD Tablets),” launched in June 2024, have exceeded plan and remained strong. In August 2024, we began providing information on the first large-scale authorized generic products launched since the company joined the Group, “Rivaroxaban Tablets (reference product: Xarelto® Tablets)” and “Rivaroxaban OD Tablets (reference product: Xarelto® OD Tablets),” and obtained marketing approvals for 2 new authorized generic products, “Loxoprofen Na Tape (reference product: Loxonin® Tape)” and “Hydroxychloroquine Sulfate Tablets (reference product: Plaquenil® Tablets).”」

「Following the addition of 第一三共エスファ株式会社 to the Group, we established the Pharmaceutical Business Promotion Department in April 2024 to provide management support. We will also focus on developing new products and expanding our pipeline to build a foundation for sustainable growth.」

「In the pharmaceutical manufacturing and marketing business, we are pursuing initiatives to realize synergies from bringing 第一三共エスファ株式会社 into the Group. In addition to existing products, we continue to promote sales of the COVID-19 antigen test kit “テガルナ®スティックSARS-CoV-2 Ag,” which was launched in December 2022, although sales have been affected by drug price revisions and soaring raw material prices.」

「In the pharmaceutical manufacturing and marketing business, while affected by annual drug price revisions and rising costs for raw materials and other inputs, we began selling the COVID-19 antigen test kit “テガルナ®スティック SARS-CoV-2 Ag” in December 2022. We aim to develop and sell new products in order to expand the business while maintaining a stable supply of pharmaceuticals.」

「In light of this situation, once the COVID-19 antigen test kit currently under application, for the novel coronavirus (SARS-CoV-2), is approved, we will focus on sales and contribute to preventing the spread of infectious diseases.」

「In the pharmaceutical manufacturing and marketing business, sales generated through joint promotions with major partner pharmaceutical companies remain strong. We will continue promoting sales of our products and use the update of the manufacturing execution system (MES) to visualize manufacturing processes and support workers, thereby improving profitability.」

「In addition to continuing to promote sales of our products, we are preparing to update the manufacturing execution system, which visualizes manufacturing processes and provides instructions and support to workers.」

「In addition to continuing to promote sales of our products, we are preparing to update the manufacturing execution system (MES), which visualizes manufacturing processes and provides instructions and support to workers. Through this, we aim to improve quality control and productivity and prevent human error.」

「In the pharmaceutical manufacturing and marketing business, we will continue promoting sales of our products and conducting joint promotions with major partner pharmaceutical companies, while preparing to update the manufacturing execution system (MES), which visualizes manufacturing processes and provides instructions and support to workers. We will continue to enforce compliance to ensure quality control and a stable supply.」

「In the pharmaceutical manufacturing and marketing business, we improved earnings by promoting sales of our products at our insurance pharmacies, conducting joint promotions with major partner pharmaceutical companies, and handling investigational drugs. We are also continuing to strengthen our capabilities as a pharmaceutical company through investments in plant equipment, the recruitment of specialized personnel and organizational restructuring, and are working to expand the business, including contract manufacturing.」

「In the pharmaceutical manufacturing and marketing business, we improved earnings by promoting sales of our products within the Group and reviewing expenses. We are also continuing to strengthen our capabilities as a pharmaceutical manufacturer through investments in plant equipment, the recruitment of specialized personnel and organizational restructuring, and are working to expand the business, including contract manufacturing.」

「In the pharmaceutical manufacturing and marketing business, we improved earnings by promoting sales of our products within the Group and optimizing costs. We are also continuing to strengthen our capabilities as a pharmaceutical manufacturer through investments in plant equipment, the recruitment of specialized personnel and organizational restructuring, and are establishing a structure for expanding the business, including contract manufacturing.」

「In the pharmaceutical manufacturing and marketing business, we aim to expand the business at an early stage as our third pillar toward achieving our medium-term targets. We will strengthen each function as a pharmaceutical manufacturer and improve productivity to build the foundations for launching new products and expanding contract manufacturing.」

「From the third quarter of the fiscal year, we have been promoting sales of our products through the Group’s insurance pharmacies and working to expand the business. We are also strengthening the foundations of each division to support further business expansion. In research and development, we are strengthening our internal structure in preparation for launching our products and other offerings. In manufacturing, we are investing in new equipment and improving our technical capabilities to support contract manufacturing for major pharmaceutical companies. In sales, we are reviewing the organizational structure and using IT tools to improve the sales efficiency of our medical representatives.」

「As the first step toward entering and expanding the business, we acquired all shares of 藤永製薬株式会社 on 8 August 2019.」

「As the first step toward entering and expanding the pharmaceutical manufacturing and marketing business, the company will acquire all shares of 藤永製薬株式会社, as described in the “Notice Regarding the Acquisition of Shares in 藤永製薬株式会社 (Making It a Subsidiary)” announced on 31 July 2019.」